Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 6, 1996, Pages 1376-1381

  Locher, Hans H ^a,b   Schlunegger, Heidi ^a   Hartman, Peter G ^a   Angehrn, Peter ^a   Then, Rudolf L ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; DAPSONE; DIHYDROFOLATE REDUCTASE INHIBITOR; EPIROPRIM; OXACILLIN; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEPTICEMIA; STAPHYLOCOCCUS INFECTION;

EID: 0030024198     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.6.1376     Document Type: Article

References (14)

1. Angehrn, P., P. Hohl, C. Hubschwerlen, M. Page, and R. L. Then. 1992. Antibacterial properties of Ro 40-6890, a broad-spectrum cephalosporin, and its novel orally absorbable ester, Ro 41-3399. Antimicrob. Agents Chemother 36:2825-2834.
2. Brun-Pascaud, M., C. F. Derovin, and P. M. Girard. 1995. Experimental evaluation of epiroprim alone or combined with dapsone in dual pneumocystosis and toxoplasmosis infection in a rat model, abstr. B53, p. 35. In Program and abstracts of the 35th Inteiscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Chang, H. R., D. Arsenijevic, R. Comte, A. Polak, R. L. Then, and J. C. Pechere. 1994. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor alone and in combination with dapsone against Toxoplasma gondii. Antimicrob. Agents Chemother 38:1803-1807.
4. Dubé, M. P., and F. R. Sattler. 1993. Prevention and treatment of opportunistic infections. Curr. Opin. Infect. Dis. 6:230-236.
5. Eliopoulos, G. M., and R. C. Moellering. 1992. Antimicrobial combinations, p. 432-492. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore
6. Finney, D. J. 1978. Statistical method in biological assay, 3rd ed Charles Griffin & Co., Ltd., London.
7. Jorde, U. P., H. W. Horowitz, and G. P. Wormser. 1993. Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals. AIDS 7:355-359
8. Lambertus, M. W., R. Y. Kwok, and M. E. Mulligan. 1990. In vitro susceptibilities of oxacillin-resistant Staphylococcus aureus to dapsone and sulfamethoxazole alone and in combination with trimethoprim. Antimicrob. Agents Chemother. 34:1453-1455.
9. Mehlhorn, H., W. Dankert, P. G. Hartman, and R. L. Then. 1995. A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models Parasitol. Res. 81: 296-301.
10. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed, vol. 13, no. 25, M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
11. Then, R. L., P. Angehrn, W. Cullmann, H. H. Locher, and P. G. Hartman. 1993. Properties of epiroprim (Ro 11-8958) as an antibacterial agent, abstr. 383, p. 189. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D C.
12. Then, R. L., P. G. Hartman, I. Kompis, M. Stephan-Güldner, and K. Stöckel. 1994. Epiroprim. Drugs Future 19:446-449.
13. Wallace, R. J., D. R. Nash, L. C. Steele, and V. Steingrube. 1986. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth J. Clin Microbiol. 24:976-981.
14. Walzer, P. D., J. Foy, P. Steele, and M. White. 1993. Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. Antimicrob. Agents Chemother 37:1436-1443.